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Abstract
A recent gamma-retroviral clinical Chronic Granulomatous Disease (CGD) gene therapy
(GT) trial achieved proof-of-concept but was accompanied by activation of oncogenes
and transgene silencing. The ubiquitous chromatin opening element (UCOE) comprises
the sequences of two divergently oriented house-keeping gene promoters and is known
to have anti-silencing properties. In a screen we identiﬁed two novel UCOE constructs
that prevent adjacent promoter methylation in P19 cells. Experiments were continued
with the shorter UCOE constructs in induced pluripotent stem cells (iPSC) derived from
a p47phox-deﬁcient CGD patient. The iPSC line was transduced with the lentiviral GT
vectors expressing p47 under the constitutively active SFFV promoter with UCOE ele-
ment (UCOE_SF) and without UCOE element (SF) adjacent to the SFFV promoter. The
iPSCwere expanded before propagation towards neutrophils. 20 days after transduction
the UCOE_SF vector was protected from methylation in iPSC as previously shown in
P19 cells, whereas the SF vector was heavily methylated in iPSC. The UCOE_SF vector
maintained stable transgene expression in iPSC, macrophages and neutrophils, whereas
the SF vector was strongly silenced. The UCOE_SF vector stably restored ROS produc-
tion in neutrophils, whereas for the SF vector the count of ROS producing cells was
marginal. To conclude, we have shown that the prevention of transgene silencing by
UCOE is functionally and mechanistically preserved upon terminal neutrophil diﬀeren-
tiation.
Introduction
The primary immunodeﬁciency Chronic Granulomatous Disease (CGD) is caused by a
defective NADPH-oxidase complex, which is the molecular machinery required for the
production of reactive oxygen species (ROS) that facilitate microbial killing by phago-
cytes. The disease is characterized by recurrent severe bacterial and fungal infections
requiring prophylactic treatment of the patients with antibiotics and antimycotics. The
state-of-the-art curative therapy for CGD is bonemarrow transplantation if a HLA iden-
tical donor is available. Unfortunately, depending on the ethnic group, a HLA identical
donor is available for only about 16–75% of CGD patients [1]. For patients without HLA
matching BM donor, a gene therapy (GT) approach using autologous bone marrow cells
might be an alternative therapeutic option.
For the X-chromosomal form of CGD (X-CGD) a clinical phaseI/II trial was initiated in
2005 utilizing a γ-retroviral GT vector. This GT vector drives gp91phox transgene ex-
pression by the viral long terminal repeat (LTR). The clinical trial was temporarily suc-
cessful as gene modiﬁed stem cells engrafted in the bone marrow in signiﬁcant amount
which led to the restoration of ROS production in peripheral phagocytes and to the dis-
appearance of life threatening infections within about 50 days after GT. Unfortunately
GT was accompanied by two major adverse events; Oncogene transactivation by en-
hancer sequences within the LTR sequence of the GT vector led to clonal dominance
which partially progressed to myelodysplastic syndrome and monosomy 7 requiring
medical intervention. Furthermore an increasing discrepancy between gene marking
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and functionality over time was observed resulting in decreased therapeutic eﬃciency.
A detailed analysis revealed DNA-methylation within the viral LTR promoter sequence
as the molecular cause for decreasing therapeutic eﬃciency [2] [3] [4].
This study focuses on the development of a silencing resistant GT vector for the p47phox
deﬁcient form of CGD.We used the constitutively active viral LTR of spleen focus form-
ing virus (SFFV) driving p47phox transgene expression as this sequence within the LTR
was sensitive to DNA methylation in the above mentioned clinical trial. To prevent
transgene silencing we used the ubiquitous chromatin opening element (UCOE), which
is published, to prevent methylation when inserted 5’ of SFFV promoter [5] [6] [7] but
which has not been analyzed in neutrophils in a CGD-speciﬁc context up to now. As
the UCOE element possesses intrinsic promoter activity we generated various UCOE
deletion constructs. Our constructs were initially tested in P19 cells known for their
high DNA methylation activity. Main experiments were conducted in a p47phox CGD
patient derived induced pluripotent stem cell (iPSC) line [8] as a CGD disease model
to test the silencing of the GT vectors. The p47phox deﬁcient iPSC were transduced
with the GT vectors and propagated to neutrophils. The gene corrected cells were again
tested for promoter methylation in iPSC, and after diﬀerentiation to neutrophils, cells
were tested for expression of p47phox transgene and restoration of ROS production.
Objective
We analyzed a UCOE construct for its capacity to protect the strongly silencing sensitive
SFFV LTR promoter from inactivation in a disease model which reﬂects the CGD disease
as well as the long term epigenetic processes observed in vivo, in order to combine this
UCOE construct in a second step with a tissue-speciﬁc promoter for CGD gene therapy
vector development.
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a
Figure Legend
Figure 1. Gene therapy of iPSC and diﬀerentiation to neutrophils.
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(A) Workﬂow of iPSC Work. Methylene blue/eosin staining shows that early yield of
neutrophil factories contain cells with band cell morphology (neutrophil progenitors),
whereas late yield of the factory contains cells withmature neutrophilmorphology (with
the neutrophil typical multi-lobal segmented nuclei) and also macrophage morphology
(with single round nuclei).
(B) p47 expression in OCT3/4 gated iPSC over time. P47 expression of UCOE_ SF_p47
is stable over time, but decreases in SF_p47 transduced cells.
(C) DNAmethylation analysis in iPSC after 20 days of culture. CpG dinucleotides in in-
dividual subcloned PCR products are shown in horizontal orientation with black/white
circles indicating methylated/unmethylated CpGs. UCOE protects the SFFV promoter
from methylation, whereas unprotected SFFV promoter is strongly methylated in iPSC
20 days after transfection.
(D) Gating strategy and p47 expression in yield of neutrophil factory day 68 after trans-
duction. p47 expression of UCOE_ SF_p47 is maintained at high level in neutrophils
(FCSlow (gate A), CD15+CD14- (gate N)) and in macrophages (FCSlow, CD14+CD15-
(gateM)), but signiﬁcantly reduced in SF_p47 transduced cells in comparison to p47phox
expression in iPSC on day 6 (Fig. 1B).
(E) Detection of ROS production in diﬀerentiated CD15+ neutrophils in a dihydrorho-
damine 123 assay. ROS production leads to increased ﬂuorescence resulting in a shift
to the right. Percentage of ROS producing neutrophils is high for UCOE_ SF_p47, but
marginal in SF_p47 in comparison to p47phox expression in iPSC on day 6 (Fig. 1B).
Results & Discussion
UCOE prevents promoter methylation in P19 cells
A previously described plasmid with full length UCOE sequence [6] was used to gener-
ate deletion constructs of this UCOE element. These constructs were then cloned into
gamma-retroviral vectors 5’ to the silencing sensitive SFFV promoter (Suppl. Fig. 1A).
P19 cells with high DNA methylation activity were retrovirally transduced with the
generated UCOE/SFFV fusion constructs and SFFV promoter methylation was analyzed
(Suppl. Fig. 1B). This screen revealed two UCOE constructs which in only one orien-
tation UCOE1794fwd and UCOE1662fwd protected the adjacent SFFV promoter from
silencing. The analysis was repeated after introducing the two UCOE/SFFV fusion con-
structs into lentiviral vector backbones [9]. Similarly, both UCOE constructs protected
the adjacent SFFV promoter from inactivation in P19 cells (Suppl. Fig. 2).
UCOE prevents SFFV promoter methylation in iPSC and maintains stable ex-
pression in iPSC derived neutrophils
As P19 cells can’t be propagated to phagocytes, we transduced cells of a p47phox-
deﬁcient iPSC cell line with the lentiviral GT vectors SF and UCOE_SF with targeted
MOI 2 and expanded them before diﬀerentiation to neutrophils alongside the untrans-
duced CGD iPSC line as negative control and the embryonic stem cell line HUES2 as
positive control. Some of the iPSC were expanded until day 20 for p47 expression anal-
ysis and promoter methylation analysis. The percentage of p47 expressing iPSC was
assayed by ﬂow cytometry at 4 timepoints. The Oct3/4 pluripotency marker was used
to identify iPSC (Fig. 1B). The percentage of p47-positive cells for the SF vector trans-
duced cells decreased from 33.11% at day 6 to 17.39% at day 20, whereas in UCOE_SF
transduced cells the percentage only marginally declined from 56.77% at day 6 to 48.43%
at day 20. Methylation of the SFFV promoter was assayed at day 20 after transduction
in iPSC. Similarly to P19 cells, the SFFV promoter was protected from methylation in
UCOE_SF (12.1% of CpGs methylated), whereas the SF was heavily methylated (74.1%
of CpGs methylated).
UCOE maintains stable expression and enables stable ROS production in iPSC-
derived neutrophils
The iPSC were diﬀerentiated to neutrophils with an embryoid body (EB) based diﬀeren-
tiation protocol that releases a mixture of neutrophils and macrophages into the super-
natant (Fig. 1A). In early phase of culture maturation, EB supernatant contained band
cells (progenitors of neutrophils). In advanced stage of culture maturation (Fig. 1A, 1D)
the EB supernatant contained macrophages, and mature neutrophils with multi-lobal
segmented nuclei.
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p47phox transgene expression was analyzed in macrophage and neutrophil cell popu-
lations deﬁned by surface markers (Fig. 1D). Within the CD14+/CD15- (Fig. 1D, gate
M) and in the CD14-/CD15+ (Fig. 1D, gate N) populations the percentages of p47 ex-
pressing cells were high for UCOE_SF vector (gate M: 57.78%; gate N: 43.58%) and very
low for unprotected SF vector (gate M: 10.04%; gate N: 5.22%). Together with the known
anti-silencing properties of our UCOE construct (Fig. 1C), the low p47phox expres-
sion in the absence of the UCOE element is likely due to promoter methylation during
the diﬀerentiation of iPSC to neutrophils. More important than transgene expression
is functional correction of neutrophilic ROS production. The ﬂow cytometry based di-
hydrorhodamine 123 (DHR) assay was used to detect ROS production upon stimulation
with PMA. In CD14-/CD15+ neutrophils UCOE_SF restored ROS production in 34.99% of
cells. The percentage of ROS producing neutrophils derived from UCOE_SF transduced
iPSC was in the same range as in neutrophils derived from HUES2 positive control.
In contrast to these results, p47phox expression and ROS production in cells obtained
from SF vector transduced iPSC was marginal (1.94%) again pointing towards epigenetic
inactivation of the unprotected SFFV promoter in the SF vector.
In order to prevent silencing of the SFFV promoter we analyzed SFFV promoter and
ubiquitous chromatin opening element (UCOE) – SFFV promoter fusion constructs for
DNA methylation in a highly DNA methylating embryonic carcinoma cell line and in
iPSC.The UCOE element consists of two divergently oriented CpG island housekeeping
gene promoters, CBX3 and HNRPA2B1. The UCOE element was reported to be resis-
tant to silencing and to reduce integration site eﬀects on transgene expression levels
independent of vector copy number [6]. Its anti-silencing eﬀect was not restricted to
the UCOE sequence itself but expanded to adjacent promoter sequences including an
adjacent SFFV promoter [5].
This reported UCOE eﬀect was orientation dependent. Only a UCOE element in which
SFFV was fused to the CBX3 promoter element (A2B1-CBX3-SFFV termed 3’UCOE or
“forward” in [5] corresponding to our reverse orientation) was reported to prevent SFFV
promoter silencing [5]. In our hands, only two of our UCOE deletion constructs (1797bp
(UCOE1797fwd) and 1662bp (UCOE1662fwd)) and both only in CBX3-A2B1-SFFV (for-
ward, fwd) orientation (Suppl. Fig. 1) were able to prevent SFFV promoter silencing. It
is worth noting that the UCOE elements used in our study and in the study of Zhang
and coworkers diﬀered in size.
The anti-silencing eﬀect of our UCOE1662fwd element was independent of viral back-
ground (gamma-retrovirus and lentivirus) and could be reproduced in P19 cells and in
the iPSC model. Furthermore, the GT vector Lenti UCOE 1662fwd SFFV p47 (UCOE
SF) showed stable transgene expression in iPSC and in iPSC derived macrophages and
neutrophils.
For the endogenous native UCOE sequence, it is known that the open DNA confor-
mation is associated with depletion of nucleosomes and changes in histone code and
demethylation of DNA around the UCOE promoters [10]. Authors could show an accu-
mulation of histones related to active transcription of H3K9Ac, H3K14Ac, H3K4me2,
H3K4me3 and histones related to open chromatin conformation H4K4Ac, H4K7ac,
H4K11Ac and H4K14Ac which is mandatory for transcription. We therefore hypothe-
size that this histone code spreads from the UCOE element into adjacent SFFV promoter
region and thereby prevents promoter methylation and transgene silencing. Recently
the site with anti-silencing activity could be restricted to a core region of UCOE span-
ning only 455bp of the CBX3 part of UCOE in the authers 3’ orientation [11], corre-
sponding to our reverse orientation. The reason why individual constructs of diﬀerent
sizes possess anti-silencing activity in only one orientation remains enigmatic and re-
quires further investigation.
Conclusions
We have described a silencing resistant gene therapy vector with stable expression of
p47phox transgene in a highly DNA methylating embryonic carcinoma cell line as well
as in iPSC, and upon iPSC diﬀerentiation to neutrophils and macrophages. Due to the
stable transgene expression this vector was able to facilitate full restoration of ROS pro-
duction in neutrophils obtained from transduced p47phox CGD iPSC.
Limitations
TheSFFV promoter served as amodel system due to its susceptibility to silencing in vivo.
For gene therapy vector DNA methylation studies, the unprotected SFFV promoter and
the UCOE protected SFFV promoter are reliable positive and negative controls. Further
studies are required to conﬁrm whether UCOE elements described in this study and in
the study described by [11] are able to protect tissue speciﬁc promoters [9] [12] [13] as
well, which might add to long term performance of these gene therapy vectors in vivo,
respectively if those promoters need silencing protection after all.
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